ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

KURA Kura Oncology Inc

20.28
0.66 (3.36%)
01 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Kura Oncology Inc KURA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.66 3.36% 20.28 16:30:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
19.63 19.63 20.81 20.28 19.62
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202406:30GLOBEKura Oncology to Report First Quarter 2024 Financial Results
22/4/202406:30GLOBEKura Oncology Receives Breakthrough Therapy Designation for..
10/4/202406:30GLOBEKura Oncology to Participate in Stifel Targeted Oncology..
05/4/202406:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
06/3/202406:30GLOBEKura Oncology Reports First Patient Dosed in Trial of..
01/3/202416:00GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
27/2/202415:52EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202415:03EDGAR2Form 8-K - Current report
27/2/202415:01GLOBEKura Oncology Reports Fourth Quarter and Full Year 2023..
26/2/202406:30GLOBEKura Oncology Doses First Patient in KOMET-008 Trial of..
22/2/202406:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
20/2/202406:30GLOBEKura Oncology to Report Fourth Quarter and Full Year 2023..
15/2/202415:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
14/2/202416:58EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202416:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202416:21EDGAR2Form S-3 - Registration statement under Securities Act of..
02/2/202406:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
31/1/202416:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202416:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202416:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202415:10EDGAR2Form 144 - Report of proposed sale of securities
30/1/202406:08EDGAR2Form 8-K - Current report
30/1/202406:00GLOBEKura Oncology Reports Positive Preliminary Ziftomenib..
26/1/202416:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202415:08EDGAR2Form 8-K - Current report
24/1/202415:12EDGAR2Form 144 - Report of proposed sale of securities
24/1/202406:00GLOBEKura Oncology Announces Oversubscribed $150 Million Private..
04/1/202415:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202308:01EDGAR2Form 8-K - Current report
11/12/202315:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202306:30GLOBEKura Oncology’s Menin Inhibitor Ziftomenib Selected for The..
28/11/202306:30GLOBEKura Oncology to Participate in the JMP Securities..
02/11/202315:39EDGAR2Form S-3ASR - Automatic shelf registration statement of..
02/11/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202315:03EDGAR2Form 8-K - Current report
02/11/202315:01GLOBEKura Oncology Reports Third Quarter 2023 Financial Results
02/11/202306:30GLOBEKura Oncology and Mirati Therapeutics Enter into Clinical..
30/10/202306:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
26/10/202315:05GLOBEKura Oncology to Report Third Quarter 2023 Financial Results
19/10/202306:30GLOBEKura Oncology Announces First Patient Dosed in FIT-001 Trial..
17/10/202315:05GLOBEKura Oncology Announces Positive Results from..
04/10/202306:30GLOBEKura Oncology Announces Three Presentations at..
28/9/202306:30GLOBEKura Oncology Reports Preclinical Data Showing Ability of..
19/9/202306:30GLOBEKura Oncology to Participate in Cantor Global Healthcare..

Su Consulta Reciente

Delayed Upgrade Clock